OX40/OX40L blockade in vivo is generally effective in many models with autoimmune diseases, mainly by inhibiting activation and migration of CD4+ T cells and altering cytokine production (34, 118, 119) (Table 3). Here, TNFSF4 is linked to autoimmune disease.